Literature DB >> 11730673

Interferon therapy for orbital infiltration secondary to Erdheim-Chester disease.

B Esmaeli1, A Ahmadi, R Tang, J Schiffman, R Kurzrock.   

Abstract

PURPOSE: To describe a 55-year-old male with Erdheim-Chester disease with bilateral orbital infiltration and visual loss who was successfully treated with interferon-alpha.
METHODS: Interventional case report.
RESULTS: The patient was treated with interferon-alpha and had an improvement in his clinical signs, including his visual acuity, after 4 weeks of interferon therapy.
CONCLUSION: Interferon-alpha can be effective in the treatment of orbital infiltration secondary to Erdheim-Chester disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11730673     DOI: 10.1016/s0002-9394(01)01141-2

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  9 in total

Review 1.  Treatment of Erdheim-Chester disease with cladribine: a rational approach.

Authors:  C Myra; L Sloper; P J Tighe; R S McIntosh; S E Stevens; R H S Gregson; M Sokal; A P Haynes; R J Powell
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

2.  Erdheim-Chester disease of the central nervous system: new manifestations of a rare disease.

Authors:  P Sedrak; L Ketonen; P Hou; N Guha-Thakurta; M D Williams; R Kurzrock; J M Debnam
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-29       Impact factor: 3.825

3.  A tale of two histiocytic disorders.

Authors:  Filip Janku; Javier Munoz; Vivek Subbiah; Razelle Kurzrock
Journal:  Oncologist       Date:  2013-01-08

4.  Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.

Authors:  Eli L Diamond; Lorenzo Dagna; David M Hyman; Giulio Cavalli; Filip Janku; Juvianee Estrada-Veras; Marina Ferrarini; Omar Abdel-Wahab; Mark L Heaney; Paul J Scheel; Nancy K Feeley; Elisabetta Ferrero; Kenneth L McClain; Augusto Vaglio; Thomas Colby; Laurent Arnaud; Julien Haroche
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

5.  Treatment of skeletal Erdheim-Chester disease with zoledronic acid: case report and proposed mechanisms of action.

Authors:  Thitinan Srikulmontree; H Davis Massey; W Neal Roberts
Journal:  Rheumatol Int       Date:  2006-08-25       Impact factor: 2.631

6.  [Erdheim-Chester disease of the orbit with compressive optic neuropathy].

Authors:  K Manousaridis; J Casper; M P Schittkowski; H Nizze; R F Guthoff
Journal:  Ophthalmologe       Date:  2010-03       Impact factor: 1.059

Review 7.  Orbital inflammation.

Authors:  Kimberly P Cockerham; Sang H Hong; Ellen E Browne
Journal:  Curr Neurol Neurosci Rep       Date:  2003-09       Impact factor: 5.081

8.  Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim-Chester disease patients following BRAF inhibitor monotherapy.

Authors:  Roei D Mazor; Ran Weissman; Judith Luckman; Liran Domachevsky; Eli L Diamond; Omar Abdel-Wahab; Shirley Shapira; Oshrat Hershkovitz-Rokah; David Groshar; Ofer Shpilberg
Journal:  Neurooncol Adv       Date:  2020-03-03

9.  Resolved heart tamponade and controlled exophthalmos, facial pain and diabetes insipidus due to Erdheim-Chester disease.

Authors:  Jaume Monmany; Esther Granell; Laura López; Pere Domingo
Journal:  BMJ Case Rep       Date:  2018-10-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.